Infosys Q1 Results: Profit beats estimates, zooms 9% YoY to Rs 6,921 cr; revenue up 8%
Show more
Show less
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
27 minutes ago
- Mint
Small-cap pharma stock edges higher despite stock market sell-off; here's why
Stock Market Today: Small-cap pharma stock edged higher during the intraday trades on Thursday despite the stock market sell-off. Check details about Fredun Pharmaceuticals Q1 results. Fredun Pharmaceuticals Limited, a pharmaceutical formulation manufacturing company in India, reported its Q1 performance on Thursday, 31 July 2025. The Fredun Pharmaceuticals reported net profit at ₹ 6.77 Crore during the quarter ending June 2025, which was 63.82% higher compared to ₹ 4.13 crore in the year-ago quarter. As per its disclosed unaudited financials for the first quarter of fiscal year 26, the revenues at ₹ 119.86 crore grew 52.08% compared to ₹ 78.81 crore in the year-ago quarter. The boost to the bottom line was further provided by the improved operating performance. The Earnings before interest, tax, depreciation, and amortization, or EBITDA, at ₹ 16.99 crore grew 62.15% over ₹ 10.48 crore in the year-ago quarter Fredun Medhora, Managing Director, in a statement said that We are pleased to report a strong start to FY26 with a significant year-on-year growth in net profit and healthy improvement across all key financial metrics." The performance as per Medhora reflects the successful execution of our growth strategy and the continued demand for the company's diversified portfolio across domestic and international markets. The company's generics portfolio continues to strengthen, with over 1,200 products currently under registration. The current order book stands at over ₹ 200 crore, providing strong revenue visibility and momentum for the upcoming quarters. The company is diversified into generics, cosmetics, nutraceuticals, mobility, and animal healthcare products too. Fredun Pharmaceuticals share price opened at ₹ 1017.00 and gained further to RS 1020 levels on Thursday , marking intraday gains of 4.73% compared to previous day's closing price of ₹ 973.95 for the Fredun Pharmaceuticals share price The gains for the small-cap stock Fredun Pharmaceuticals share price were despite weak Indian stock markets on a day when Sensex corrected mor than 1% during intraday trades amid stock market sell-off. Disclaimer: The views and recommendations made above are those of individual analysts or brokerage companies and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Deccan Herald
27 minutes ago
- Deccan Herald
Brigade Hotel Ventures shares drop nearly 10 pc in market debut trade
New Delhi, Shares of Brigade Hotel Ventures Ltd on Thursday listed with a discount of nearly 10 per cent against the issue price of Rs stock began trading at Rs 82, down 8.88 per cent from the issue price on the the NSE, it started trading at Rs 81.10, a discount of 9.88 per company's market valuation stood at Rs 3,279.94 initial share sale of Brigade Hotel Ventures Ltd fetched 4.48 times subscription on the closing day of bidding on initial public offering (IPO) had a price band of Rs 85-90 per Hotel Ventures' IPO was entirely a fresh issue of equity shares worth Rs 759.6 crore with no offer-for-sale (OFS) from the issue to the tune of Rs 468.14 crore will be used for the payment of debt, Rs 107.52 crore will be utilised for the purchase of an undivided share of land from the promoter, BEL, and the remaining funds will support acquisitions, other strategic initiatives, and general corporate Hotel Ventures Ltd is a subsidiary of Bengaluru-based real estate company Brigade Enterprises Ltd (BEL)..BEL entered into the hospitality business in 2004 with the development of its first hotel, Grand Mercure Bangalore, which commenced operations in company has a portfolio of nine operating hotels across Bengaluru, Chennai, Kochi, Mysuru, and the GIFT City (Gujarat) with 1,604 hotels are operated by global marquee hospitality companies such as Marriott, Accor and InterContinental Hotels Group.
Mint
27 minutes ago
- Mint
Tata Motors fends off investor skepticism on $4.4 billion Iveco acquisition
Tata Motors Ltd assuaged investor concerns over its acquisition of Italian truck and bus maker Iveco for $4.4 billion, reasoning that it would help generate more returns for shareholders when it starts trading as a standalone entity later this year. Less than 12 hours after Tata Motors announced its largest acquisition ever, its management fielded questions from analysts and investors over the rationale for the acquisition. 'It is a meaningful, large acquisition… There is an understanding between the two companies to build a business of scale and size,' chief financial officer P.B. Balaji said during the call. Achieving high growth in the commercial vehicle business isn't easy and India's largest commercial vehicle maker needs such acquisitions to deliver growth to shareholders, the management added. 'Market shares are highly stable in the commercial vehicle business. It is not a very disruptive business. Diversification of cash flows is important to maintain growth in the business,' Balaji explained. Tata Motors shares were up 0.28% at ₹ 670.30 each in early afternoon trade on NSE. After the deal was announced late Wednesday, investors noted the possibility of a boost in earnings. But they also raised concerns as previous similar acquisitions—such as that of South Korea-based Daewoo's commercial vehicle business for $102 million in 2004—did not result in meaningful gains in the international markets. Some investors also highlighted challenges post Tata Motors's acquisition of UK-based Jaguar Land Rover in 2008 for $2.3 billion, and Tata Steel Ltd's acquisition of Corus Plc., also based in the UK, for $13.1 billion in 2007. 'Given the group's challenging experience with Corus and JLR acquisitions, why do you think this is somewhere Tata Motors can create value?,' asked Sonal Gupta, head of research-equities, at HSBC Asset Management India. 'Tata Motors CV (commercial vehicles) has limited international presence. We haven't really been able to capitalize the tech from Tata Daewoo to grow internationally.' Balaji said Tata Motors's portfolio and business level were close to that of Iveco, an acronym for Industrial Vehicles Corp., and the newly formed entity post the acquisition would invest up to $1.7 billion each year. 'Opportunities like these do not come when you want. You move when such opportunities arise. There was a very small window to get this business,' the CFO told the investors and analysts in attendance. On the JLR and Daewoo acquisitions, Balaji said JLR was a premium-luxury player and Tata Motors was a mass player at the time of acquisition, resulting in some hiccups, while Daewoo was a small deal limited to a single market. 'We have had our learnings from the experience,' Balaji assured investors. During Thursday's call, analysts from Morgan Stanley, Kotak Institutional Equities, and Bank of America raised questions about the calculation of free cash flow expectations and potential earnings boost. Per the company's estimate, Tata Motors and Iveco would have a significant combined global presence, with sales of over 540,000 units and over $25 billion in revenue. Europe would account for half of the combined group's total sales, followed by 35% in India and the remaining 15% in the Americas. Tata Motors lined up $4.36 billion in funding from Morgan Stanley Bank NA, Morgan Stanley Senior Funding Inc., and MUFG Bank Ltd for the acquisition, the company said in a statement on Wednesday. The company will look for fundraising opportunities to repay the debt, of which 30-40% will be equity and 60-70% will be debt, it added. Tata Motors said the acquisition of Iveco will allow the company to enter geographies like Latin America, where it was not previously possible due to fund and network constraints. In a note on Wednesday, analysts at Nuvama Institutional Equities said the acquisition would lead to an earnings boost for Tata Motors, with earnings per share estimated to increase by 4%. 'However, the key downside risk for Iveco is possibility of a sales downcycle in Europe and US CV markets resulting in lower earnings in near-term,' they wrote. The commercial vehicle business is the second largest for Tata Motors, contributing 17% to its 2024-25 revenue. However, the business's overall sales volume declined 5%, although exports grew 3%. Since the first confirmation of advanced talks of a deal between Tata Motors and Iveco on 30 July, Tata Motors shares have fallen by 3% while the Nifty Auto shed 1%.
